Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials
Sonali M. Smith, Brandelyn N. Pitcher, Sin Ho Jung, Nancy L. Bartlett, Nina Wagner-Johnston, Steven I. Park, Kristy L. Richards, Amanda F. Cashen, Anthony Jaslowski, Scott E. Smith, Bruce D. Cheson, Eric Hsi, John P. Leonard
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials'. Together they form a unique fingerprint.